Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.